Durect Corp (NAS:DRRX)
$ 0.88 -0.0325 (-3.56%) Market Cap: 27.32 Mil Enterprise Value: 30.68 Mil PE Ratio: 0 PB Ratio: 22.56 GF Score: 60/100

DURECT Corp To Discuss Agreement Call Transcript

Dec 22, 2021 / 01:30PM GMT
Release Date Price: $9.7 (-0.31%)
Operator

Greetings, and welcome to the DURECT Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the call over to Mike Arenberg, Chief Financial Officer. Thank you. You may begin.

Michael H. Arenberg
DURECT Corporation - CFO & Secretary

Good morning, and welcome to our call to discuss our license agreement with Innocoll Pharmaceuticals. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation.

Before beginning, I would like to remind you of our safe harbor statement. During the course of this call, we may make forward-looking statements regarding DURECT's products and development, expected product benefits, our development plans, future clinical trials, our projected financial results. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Further information regarding these and other risks can be found in our SEC filings, including our 10-K and 10

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot